To investigate whether Barrett's metaplasia may develop despite effective medical therapy.
Summary Background Data
Gastroesophageal reflux disease has a multifactorial etiology. Therefore, medical treatment may not prevent complications of reflux disease.
Methods
Eighty-three patients with reflux disease and mild esophagitis were prospectively studied for the development of Barrett's metaplasia while receiving long-term therapy with proton pump inhibitors and cisapride. Only patients who had effective control of reflux symptoms and esophagitis were included. The surveillance time was 2 years. The outcome of these 83 patients was compared with that of 42 patients in whom antireflux surgery was performed with a median follow-up of 3.5 years.
Results
Twelve (14.5%) patients developed Barrett's while receiving medical therapy; this was not seen after surgery. Patients developing Barrett's had a weaker lower esophageal sphincter and peristalsis before treatment than patients with uncomplicated disease.
Conclusions
Antireflux surgery is superior to medical therapy in the prevention of Barrett's metaplasia. Therefore, patients with reflux disease who have a weak lower esophageal sphincter and poor esophageal peristalsis should undergo antireflux surgery, even if they have only mild esophagitis.
Gastroesophageal reflux disease (GERD) is a disease with multifactorial etiology. 1 The impaired lower esophageal sphincter (LES) is the basic anatomic defect that enables reflux of gastric contents into the esophagus. 2 Gastric acid may play an important role in the pathophysiology of acute reflux esophagitis. 1 However, GERD is a general motility disorder of the foregut. It may lead to deterioration of esophageal peristalsis, which impairs esophageal clearance function. 3 This prolongs the presence of the refluxate in the esophagus and may therefore enhance esophageal mucosal damage. 4 Moreover, GERD may result in alteration of gut neuropeptides that are important for the control of antroduodenal motility. 5 Weak antroduodenal motility during the fasting state impairs the clearance function of the stomach and may cause pathologic duodenogastric reflux. 6 Increased concentrations of duodenal contents have been shown in patients with GERD, especially those with Barrett's metaplasia. 7 Duodenogastroesophageal reflux causes growth stimulation of the foregut mucosa, 8 may enhance production of oxygen-derived free radicals, 9 -11 and may alter apoptosis in the esophageal mucosa. 12 These mechanisms may explain the carcinogenic potential of GERD. 13, 14 Because of the wide spectrum of pathophysiologic mechanisms in GERD, medical treatment aimed at suppressing gastric acid production does not completely inhibit reflux of all gastroduodenal contents. Therefore, it may be concluded that medical therapy in GERD may not prevent the development of complications such as Barrett's metaplasia, although patients are free of heartburn and acute esophagi-tis. 15 It was the aim of this prospective study to investigate whether Barrett's metaplasia may develop despite effective medical treatment of GERD.
METHODS
Eighty-three patients with GERD receiving continuous treatment with proton pump inhibitors (PPI) in combination with cisapride were prospectively studied for the development of Barrett's metaplasia. There were 45 male (54.2%) and 38 female (45.8%) patients with a median age of 59 years (range 21-74). The median duration of reflux symptoms before the patients entered the study was 5 years (range 6 months to 20 years). Only patients with mild reflux esophagitis according to the Savary-Miller 16 classification were included, because these are patients who can probably be managed by medical therapy in the long term. The surveillance time was 2 years. Patients with PPI or cisapride treatment in the past were excluded from the study, but not patients with H 2 -blocker therapy or treatment with antacids.
Diagnosis
Reflux disease was defined by the presence of typical reflux symptoms such as heartburn and regurgitation and the presence of a hiatal hernia on endoscopy and the barium study. Patients were required to have a defective LES on manometry as defined below. Pathologic 24-hour pH monitoring was not mandatory. Patients with gastroduodenal ulcerations and those with regular use of antiinflammatory drugs or vitamin C were excluded from the study. Moreover, we manometrically excluded patients with functional disorders of the esophagus mimicking GERD. Patients with GERD who had dysphagia predominantly or had severe respiratory symptoms were excluded as well, because these patients usually have a poor response to medical therapy. 17, 18 Also, patients with GERD who had endoscopic signs of Barrett's metaplasia, such as tongues of red mucosa extending upward from the gastroesophageal junction, but not confirmed on the histologic evaluation of biopsy samples were excluded because it was likely that in these patients histology might have failed to diagnose Barrett's correctly.
Medical Therapy
Medical treatment was aimed at keeping patients free of reflux symptoms or esophagitis. Initially 43 patients (51.8%) were treated with omeprazole 20 mg daily and 40 patients (48.2%) with pantoprazole 40 mg daily. In addition, all patients received cisapride 20 mg twice daily. Seventeen patients (20.5%) of this group eventually required treatment with 40 mg omeprazole, 2 patients (2.4%) with 60 mg omeprazole, and 17 patients (20.5%) received 80 mg pantoprazole because reflux symptoms or esophagitis did not respond to the lower dose in these patients in the long term.
Further, seven patients were excluded from the study because their reflux symptoms were not relieved or they had esophagitis despite treatment with 60 mg omeprazole (n ϭ 5) or 80 mg pantoprazole (n ϭ 2). Further, 12 patients were excluded because they did not want to continue with medical treatment despite effective clinical and endoscopic control of GERD. These 19 patients decided to undergo antireflux surgery.
Surveillance
Before treatment, all patients had a clinical workup assessing heartburn and regurgitation, and all had endoscopic, radiographic, and manometric evaluation of the esophagus. In addition, 24-hour pH monitoring of the esophagus was performed. Clinical evaluation and endoscopy were repeated 3 months after medical therapy began and then at intervals of 6 months. In patients who developed Barrett's metaplasia while receiving medical therapy, medication was withdrawn and antireflux surgery was performed.
Surgical Control Group
The outcome of these 83 patients receiving medical therapy was compared with that of 42 patients with GERD who did not have Barrett's metaplasia before surgery and who underwent antireflux surgery at our department more than 2 years ago. Among these 42 patients there were 26 men (61.9%) and 16 women (38.1%). The median age was 53 years (range 26 -67). The median duration of symptoms before surgery was 6 years (range 1-20), which was not significantly different from the group of patients receiving continuous PPI treatment. Twenty-five (59.5%) of these patients had mild esophagitis and 17 (40.5%) had severe esophagitis. Preoperative evaluation and diagnosis of GERD was the same as for the patients receiving medical therapy. Indications for antireflux surgery were no response to medical therapy with PPIs in 5 (11.9%) patients, recurrence of heartburn or esophagitis in 19 (45.2%) patients, and unwillingness to continue medical therapy in 18 (42.9%) patients. The median duration of PPI treatment before surgery was 6 months (range 2 months to 2 years). Nissen fundoplication was performed in 19 (45.2%) patients with manometrically normal esophageal peristalsis, and partial posterior fundoplication was chosen in 23 (54.8%) patients with poor esophageal peristalsis. Both procedures were performed laparoscopically as previously described. 19 -21 Follow-up investigations included clinical assessment, endoscopy, manometry, and 24-hour esophageal pH monitoring. The median follow-up time was 3.5 years (range 2-5.5). Patients with GERD were included in the study only if they were free of reflux symptoms after antireflux surgery, had no acute esophagitis on endoscopy, had a normal LES on manometry, and had normal 24-hour esophageal pH monitoring results. This was the case in all 42 patients.
One further patient who developed slippage of the wrap into the chest 2 years after Nissen fundoplication was excluded from the study. In this patient, a second fundoplication was performed.
Assessment of Barrett's Metaplasia
At least four biopsy samples were taken at the gastroesophageal junction at four different sites in all of the patients before starting either therapy and during follow-up. Multiple samples were also taken from esophageal lesions. Barrett's metaplasia was diagnosed if specialized epithelium was found in the samples stained with Alcian blue or hematoxylin and eosin. 22
Esophageal Manometry
Stationary esophageal manometry was performed using a water-perfused catheter with five channels. A poor LES was diagnosed if the resting pressure measured at the respiratory inversion point was less than 8 mm Hg or the intraabdominal length of the LES was less than 1.2 cm. 2 Esophageal peristalsis was analyzed, evaluating 10 swallows of 5 mL water. Poor esophageal peristalsis was diagnosed if more than 10% of contraction waves were defective. 23, 24 Twenty-four-hour esophageal pH monitoring was performed as described by DeMeester et al. 25 A DeMeester score of more than 14.7 indicated pathologic acid reflux.
Statistical Analysis
The rate of Barrett's metaplasia in the group of patients receiving medical therapy was compared with the rate of Barrett's metaplasia after antireflux surgery using the chisquare test. Data for manometry and 24-hour pH monitoring are quoted as median and interquartile range. Manometry and 24-hour pH monitoring results before treatment were compared between patients receiving medical therapy and patients who underwent antireflux surgery using the Mann-Whitney test. This test was also used to compare manometry and 24-hour pH monitoring results between patients who developed Barrett's metaplasia and those who did not. Data on pre-and postoperative esophageal peristalsis were compared using the Wilcoxon signed-ranks test. P Ͻ .05 indicated a statistically significant difference.
RESULTS
Twelve (14.5%) patients developed Barrett's metaplasia while receiving medical therapy. In all of these patients Barrett's metaplasia was suspected on endoscopy and confirmed by histology. There were no patients with histologically diagnosed Barrett's metaplasia that was not detected on endoscopy. Nine of the patients had a short Barrett's segment and three had a long segment (3 cm in two patients, 5 cm in the third patient). None of these patients had acute esophagitis when Barrett's metaplasia was diagnosed. The development of Barrett's metaplasia based on time is shown in Figure 1 . None of the patients who underwent antireflux surgery developed Barrett's metaplasia during follow-up.
Median data of LES characteristics, esophageal body motility, and 24-hour esophageal pH monitoring results were similar between patients before medical therapy and patients before antireflux surgery (Table 1) . However, there tended to be more patients with defective esophageal body motility in the surgical group than in the patients receiving medical therapy (42.9% vs. 27.7%, P ϭ .09). There were no significant differences between the groups in terms of these parameters. Comparison of patients receiving medical therapy who developed Barrett's metaplasia with those who did not develop Barrett's metaplasia revealed a significant difference in terms of LES characteristics and esophageal body motility. Patients who developed Barrett's metaplasia had a more defective LES and more impaired esophageal peristalsis than those who did not develop Barrett's metaplasia ( Table 2 ).
There were 10 (83%) patients in the Barrett's group who had poor esophageal body motility compared with 13 (18.3%) in the group without Barrett's metaplasia (P Ͻ .05).
In terms of 24-hour esophageal pH monitoring, patients who developed Barrett's metaplasia had similar data to those who did not develop Barrett's metaplasia. The median DeMeester score was 40.5 (7.9 -87.1) in the Barrett's group versus 28.1 (16.9 -45.6) in patients without Barrett's metaplasia (not significant). However, there tended to be more patients with a normal DeMeester score in the Barrett's group than in the group without Barrett's (4 [33.3%] vs. 10 [12%], not significant).
After antireflux surgery, there was a significant improvement in esophageal peristalsis in the 23 patients who had impaired esophageal body function before surgery. In these patients, the median number of defective contraction waves improved from 60% (40 -80) before surgery to 20% (0 -40) after surgery.
DISCUSSION
Medical treatment with PPIs is an effective therapy for GERD. It heals acute esophagitis in most patients with reflux and, as shown by Klinkenberg-Knol et al, 26 may even prevent recurrence of symptoms or esophagitis in the long term if applied continuously in a sufficient dosage. However, our results indicate that continuous PPI therapy, even in combination with the prokinetic agent cisapride, does not prevent the development of Barrett's metaplasia, even though we studied only patients who were free of reflux symptoms and esophagitis during the course of medical therapy. There are no reports in the literature showing similar data. Although there is common agreement that PPIs are highly efficient at healing acute esophagitis, 26 -28 it is still a matter of debate whether long-term treatment with PPIs prevents relapse of GERD. 26 -29 In the studies by Hallerbäck et al 28 and Smith et al, 29 substantial numbers of patients had relapse of GERD symptoms or esophagitis despite maintenance treatment with 20 mg omeprazole. In the latter study, only 25% of patients with GERD were free of reflux symptoms and esophagitis after 1 year of medical therapy. 29 In fact, only Klinkenberg-Knol et al 30 showed a low rate of recurrence if omeprazole was used in a high dose. The value of this study is limited because the longterm efficacy of omeprazole was assessed by the presence or absence of grade 2 esophagitis or worse. In this study grade 1 esophagitis or typical GERD symptoms without the presence of esophagitis did not count as a relapse. Therefore, one wonders why development of Barrett's metaplasia was not observed in any of these studies, although medical therapy obviously did not control GERD in a high percentage of patients. When reading these papers one may have the impression that investigators just did not look carefully enough for the development of Barrett's metaplasia. This is supported by the fact that the possible development of Barrett's metaplasia during maintenance therapy with PPIs has neither been denied nor confirmed. Moreover, routine biopsies at the gastroesophageal junction have not been taken in most patients. In the study by van der Peet et al, 31 they reported on the efficacy of laparoscopic Nissen fundoplication in 50 patients with GERD after extensive conservative treatment. The indication for surgery was most often failure of medical therapy. Ten percent of their patients presented with Barrett's metaplasia despite long-term medical therapy. Patients with poor esophageal body function were excluded from the study and underwent partial posterior fundoplication. Because there is a strong correlation between Barrett's metaplasia and impaired esophageal peristalsis, 15 it may be suggested that the true number of patients with Barrett's metaplasia despite PPI treatment was even higher than 10%. With Klinkenberg-Knol as coauthor on this paper, it may even be speculated that some of van der Peet's patients may have been referred for surgery by Klinkenberg-Knol and thus were not doing as well on long-term treatment with omeprazole as originally reported. 30 Barrett's metaplasia has been considered a severe complication of GERD with an increased risk of malignant degeneration as a result of alterations of control mechanisms of mucosal growth. 13 Thus, it may be concluded from our data that medical therapy of GERD may not prevent reflux-induced esophageal carcinogenesis. One might argue that medical therapy failed to control the development of Barrett's metaplasia because the initial dosage of PPIs was too low, and that a higher dose was applied only if patients did not respond to the lower dose. However, the concept of medical therapy applied in our patients is similar to that used in the study of Klinkenberg-Knol et al. 26 Moreover, Lundell 27 showed that treatment of GERD with 40 mg omeprazole is not significantly superior to a dose of 20 mg omeprazole. According to this study, a higher dose of PPIs is justified only if the patient does not respond to the lower dose.
The reason why medical therapy could not prevent the development of Barrett's metaplasia in our study may have been because this entity is linked to the presence of duodenogastric reflux. It has been shown that the duodenal refluxate is most important for the development of Barrett's metaplasia. 7 Medical therapy with PPIs is highly effective at suppressing gastric acid production, and because this may reduce the volume of the refluxate, it may even decrease reflux of duodenal contents. 7 However, the reduction of duodenogastroesophageal reflux by medical therapy with PPIs is limited, and it never reaches normal levels. 7 Proton pump inhibitors increase the pH of the refluxate to a more neutral pH, and this may decrease the damaging potential of the duodenogastroesophageal refluxate. It has been shown that the duodenogastroesophageal refluxate is most toxic to the esophageal mucosa at a pH of around 5; at this pH, most of the damaging factors of the refluxate are activated. 1 But even at a neutral pH, deconjugated bile salts and trypsin can cause injury to the esophagus. 1 Thus, chronic damage to the esophageal mucosa may continue despite therapy with PPIs.
Antireflux surgery prevented the development of Barrett's metaplasia in our patients because it restores the function of the LES, thus inhibiting pathologic reflux of gastric and duodenal contents into the esophagus. 19, 21, 23 Antireflux surgery also improved esophageal peristalsis in patients with poor esophageal body motility, which is in accordance with previous studies. 17, 21, 23, 24 This may have improved esophageal clearance function, thus preventing prolonged exposure of the esophageal mucosa to gastroduodenal contents. We did not study the effect of medical therapy on esophageal peristalsis. However, significant improvement in esophageal peristalsis after medical therapy of GERD has not been reported. 3 Antireflux surgery also speeds gastric motility, as shown by Hinder et al, 32 and may therefore improve gastric clearance function, counteracting duodenogastric reflux. The same effects should be expected from treatment with cisapride. However, our results indicate that cisapride cannot improve motility disorders in GERD.
One might argue that the present trial is not a prospectively randomized study but rather a follow-up study with two different study populations. However, the two study groups were comparable in terms of demographic data, manometric findings, and 24-hour esophageal pH monitoring results. Regarding the grading of esophagitis, patients in the surgical group had more severe disease; this group included patients with severe esophagitis, whereas the medical group comprised only patients with mild esophagitis. Moreover, the surgical group also included patients in whom medical antireflux therapy had failed to control symptoms or esophagitis. Thus, if surgery were not superior to medical therapy in preventing Barrett's metaplasia, more patients with Barrett's would have been expected after antireflux surgery than after medical therapy. To perform a randomized trial in this field does not seem to be acceptable from an ethical point of view. Patients with mild esophagitis often do well on medical therapy even in the long term. 26, 27 Thus, it would not be justified to perform antireflux surgery on them without prior medical therapy. However, medical therapy often fails to control GERD in patients with severe esophagitis. 27 Therefore, it would not make sense to offer these patients long-term medical therapy just because they have been randomized to medical treatment.
The assessment of Barrett's metaplasia is sometimes difficult, especially in the presence of short Barrett's segments, as found in the majority of our patients. Improved diagnosis of Barrett's metaplasia can be achieved by routine use of Lugol staining of the esophageal mucosa during endoscopy. 33 Because we did not use this procedure and because we took only a limited number of esophageal biopsy samples, it may be suspected that Barrett's metaplasia diagnosed in patients receiving continuous medical therapy may have already been present before medical therapy was started. Therefore, one may suggest that our data do not confirm the development of Barrett's metaplasia despite medical therapy but are rather the result of diagnostic problems. However, the same diagnostic problems existed for the surgical group. If Barrett's metaplasia found in the medical group could be ascribed only to diagnostic difficulties and not to real development of this entity, Barrett's also should have been found in patients with GERD after antireflux surgery. Thus, it may be concluded that the diagnosis of Barrett's metaplasia after medical antireflux therapy in our study is due to progression of the disease and not to diagnostic errors before medical therapy started. Even though small segments of Barrett's metaplasia would have been missed at the initial diagnostic workup of patients with GERD, the fact that it was diagnosed by the same investigator subsequently during the course of medical therapy indicates that there was at least progression of the extent of Barrett's metaplasia, again showing the ineffectiveness of medical therapy to control Barrett's.
Patients with GERD who received medical therapy but developed Barrett's metaplasia had poorer esophageal peristalsis and worse function of the LES than patients who did not develop Barrett's. No significant difference was found between these two groups regarding 24-hour esophageal pH monitoring results. However, there tended to be more patients with normal pH results in the group of patients who developed Barrett's than in the latter group. Thus, we can conclude that patients with GERD who have poor esophageal peristalsis and severely impaired function of the LES should undergo antireflux surgery, especially in the case of normal esophageal pH study results and even in the presence of only mild esophagitis. Only with this strategy can Vol. 234 • No. 5
Prevention of Barrett's Metaplasia we prevent the development of Barrett's metaplasia and its malignant transformation into Barrett's carcinoma.
